Dr Reddy’s receives EU nod for AVT03 biosimilar denosumab
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
Developed in partnership with the Johns Hopkins Applied Physics Laboratory (APL), the module is built around a multi-segment RT-PCR method with integrated indexing
The ten-day initiative, running from 10 to 21 November, brings together a team of highly skilled German doctors providing life-changing reconstructive surgeries at no cost
Consolidated revenue from operations stood at Rs. 111.05 crore
Subscribe To Our Newsletter & Stay Updated